QNRX
Quoin Pharmaceuticals, Ltd.
Price Chart
Latest Quote
$4.05
+0.04 (+1.00%)
Current Price
| Previous Close | $4.01 |
| Open | $4.13 |
| Day High | $4.13 |
| Day Low | $4.04 |
| Volume | 1,470 |
Stock Information
| Shares Outstanding | 4.80M |
| Total Debt | $2.02M |
| Cash Equivalents | $10.80M |
| Net Income | $-18.67M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $19.46M |
| EPS (TTM) | $-5.67 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-723K |
| Income | $-18.67M |
| Book/sh | $1.96 |
| Cash/sh | $2.25 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 1.63 |
| Current Ratio | 1.76 |
| Debt/Eq | 51.46 |
Returns & Margins
| ROA | -114.60% |
| ROE | -575.73% |
Ownership
| Insider Ownership | 3.67% |
| Institutional Ownership | 27.80% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.27 |
| P/B | 2.07 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $20.38 |
Technical Indicators
| SMA20 | $4.27 |
| SMA50 | $5.47 |
| SMA200 | $6.16 |
| RSI | 19.63 |
| ATR | 0.3069 |
| Shares Float | 1.93M |
| Short Float | 1.41% |
| Short Ratio | 0.54 |
| Volatility | 1.75 |
| Rel Volume | 0.04 |
Performance History
| Week | +0.25% |
| Month | -23.00% |
| Quarter | -5.26% |
| 6 Months | -25.69% |
| YTD | -71.24% |
| Year | -68.73% |
| 3 Years | -97.32% |
| 5 Years | -99.99% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $4.05 | 1,470 |
| 2026-10-26 | $4.01 | 14,900 |
| 2026-10-23 | $4.02 | 2,200 |
| 2026-10-22 | $4.01 | 11,200 |
| 2026-10-21 | $3.99 | 7,800 |
| 2026-10-20 | $4.04 | 8,100 |
| 2026-10-19 | $3.98 | 15,400 |
| 2026-10-16 | $3.90 | 31,700 |
| 2026-10-15 | $4.03 | 24,100 |
| 2026-10-14 | $4.10 | 159,400 |
| 2026-10-13 | $4.15 | 26,400 |
| 2026-10-12 | $4.36 | 50,600 |
| 2026-10-09 | $4.50 | 42,500 |
| 2026-10-08 | $4.55 | 49,000 |
| 2026-10-07 | $4.70 | 26,200 |
| 2026-10-06 | $4.72 | 103,400 |
| 2026-10-05 | $4.55 | 21,100 |
| 2026-10-02 | $4.47 | 20,300 |
| 2026-10-01 | $4.72 | 17,100 |
| 2026-09-30 | $4.56 | 139,200 |
| 2026-09-29 | $4.88 | 64,200 |
| 2026-09-28 | $5.26 | 70,300 |
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
đ° Latest News
No news articles available at the moment. Check back later for updates on QNRX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $16,290,716 | $9,528,465 | $9,378,504 | $9,257,704 |
| Other Income Expense | $3,980 | $7,502 | $-2,683 | $494,544 |
| Net Non Operating Interest Income Expense | $482,081 | $558,491 | $694,614 | $-618,336 |
| Operating Expense | $16,290,716 | $9,528,465 | $9,378,504 | $9,257,704 |
| General And Administrative Expense | $6,487,909 | $5,925,833 | $6,070,517 | $6,584,868 |
| Interest Expense | - | - | $0 | $714,081 |
| Interest Expense Non Operating | - | - | $0 | $714,081 |
| Other Non Operating Income Expenses | - | - | - | $77,237 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-15,804,655 | $-8,962,472 | $-8,686,573 | $-9,381,496 |
| Net Interest Income | $482,081 | $558,491 | $694,614 | $-618,336 |
| Interest Income | $482,081 | $558,491 | $694,614 | $95,745 |
| Normalized Income | $-15,808,635 | $-8,969,974 | $-8,683,890 | $-9,798,803 |
| Net Income From Continuing And Discontinued Operation | $-15,804,655 | $-8,962,472 | $-8,686,573 | $-9,381,496 |
| Net Income Common Stockholders | $-15,804,655 | $-8,962,472 | $-8,686,573 | $-9,446,762 |
| Net Income | $-15,804,655 | $-8,962,472 | $-8,686,573 | $-9,381,496 |
| Net Income Including Noncontrolling Interests | $-15,804,655 | $-8,962,472 | $-8,686,573 | $-9,381,496 |
| Net Income Continuous Operations | $-15,804,655 | $-8,962,472 | $-8,686,573 | $-9,381,496 |
| Pretax Income | $-15,804,655 | $-8,962,472 | $-8,686,573 | $-9,381,496 |
| Interest Income Non Operating | $482,081 | $558,491 | $694,614 | $95,745 |
| Operating Income | $-16,290,716 | $-9,528,465 | $-9,378,504 | $-9,257,704 |
| Special Income Charges | - | - | $0 | $416,000 |
| Per Share | ||||
| Diluted EPS | $-14.80 | $-66.85 | $-337.47 | $-1638.23 |
| Basic EPS | $-14.80 | $-66.85 | $-337.47 | $-1638.23 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-16,194,696 | $-9,435,967 | $-9,272,115 | $-8,980,679 |
| Total Unusual Items | $3,980 | $7,502 | $-2,683 | $417,307 |
| Total Unusual Items Excluding Goodwill | $3,980 | $7,502 | $-2,683 | $417,307 |
| Reconciled Depreciation | $100,000 | $100,000 | $103,706 | $104,043 |
| EBITDA (Bullshit earnings) | $-16,190,716 | $-9,428,465 | $-9,274,798 | $-8,563,372 |
| EBIT | $-16,290,716 | $-9,528,465 | $-9,378,504 | $-8,667,415 |
| Diluted Average Shares | $1,068,152 | $133,964 | $25,741 | $5,766 |
| Basic Average Shares | $1,068,152 | $133,964 | $25,741 | $5,766 |
| Diluted NI Availto Com Stockholders | $-15,804,655 | $-8,962,472 | $-8,686,573 | $-9,446,762 |
| Gain On Sale Of Security | $3,980 | $7,502 | $-2,683 | $1,307 |
| Research And Development | $9,802,807 | $3,602,632 | $3,307,987 | $2,672,836 |
| Selling General And Administration | $6,487,909 | $5,925,833 | $6,070,517 | $6,584,868 |
| Other Gand A | $6,487,909 | $5,925,833 | $6,070,517 | $6,584,868 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $65,266 |
| Other Special Charges | - | - | - | $-416,000 |
Fetched: 2026-10-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $12,736,572 | $8,721,339 | $5,080,682 | $6,702,213 |
| Total Assets | $20,390,569 | $15,709,338 | $12,169,229 | $14,458,063 |
| Total Non Current Assets | $383,334 | $783,334 | $883,334 | $1,087,951 |
| Non Current Prepaid Assets | $0 | $300,000 | $300,000 | $383,390 |
| Goodwill And Other Intangible Assets | $383,334 | $483,334 | $583,334 | $704,561 |
| Other Intangible Assets | $383,334 | $483,334 | $583,334 | $704,561 |
| Current Assets | $20,007,235 | $14,926,004 | $11,285,895 | $13,370,112 |
| Prepaid Assets | $1,261,974 | $869,126 | $558,451 | $516,584 |
| Cash Cash Equivalents And Short Term Investments | $18,745,261 | $14,056,878 | $10,694,861 | $12,853,528 |
| Cash And Cash Equivalents | $3,818,096 | $3,623,343 | $2,401,198 | $2,860,628 |
| Current Deferred Assets | - | $0 | $32,583 | $0 |
| Cash Financial | - | - | - | $2,860,628 |
| Other Non Current Assets | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,270,663 | $6,504,665 | $6,505,213 | $7,051,289 |
| Total Non Current Liabilities Net Minority Interest | $1,723,733 | $2,323,733 | $2,923,733 | $3,523,733 |
| Tradeand Other Payables Non Current | $0 | $0 | $0 | $0 |
| Current Liabilities | $5,546,930 | $4,180,932 | $3,581,480 | $3,527,556 |
| Payables And Accrued Expenses | $5,155,004 | $4,180,932 | $3,581,480 | $3,527,556 |
| Interest Payable | $1,146,251 | $1,146,251 | $1,146,251 | $1,146,251 |
| Payables | $1,917,158 | $1,583,430 | $1,220,512 | $1,365,193 |
| Total Tax Payable | $54,936 | $77,726 | $93,989 | $159,593 |
| Accounts Payable | $1,262,222 | $905,704 | $526,523 | $605,600 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $13,119,906 | $9,204,673 | $5,664,016 | $7,406,774 |
| Total Equity Gross Minority Interest | $13,119,906 | $9,204,673 | $5,664,016 | $7,406,774 |
| Stockholders Equity | $13,119,906 | $9,204,673 | $5,664,016 | $7,406,774 |
| Gains Losses Not Affecting Retained Earnings | $-613 | $0 | - | - |
| Other Equity Adjustments | $-613 | - | - | - |
| Retained Earnings | $-70,970,447 | $-55,165,792 | $-46,203,320 | $-37,516,747 |
| Other | ||||
| Ordinary Shares Number | $52,441,360 | $8,948,164 | $987,220 | $403,840 |
| Share Issued | $52,441,360 | $8,948,164 | $987,220 | $403,884 |
| Tangible Book Value | $12,736,572 | $8,721,339 | $5,080,682 | $6,702,213 |
| Invested Capital | $13,119,906 | $9,204,673 | $5,664,016 | $7,406,774 |
| Working Capital | $14,460,305 | $10,745,072 | $7,704,415 | $9,842,556 |
| Total Capitalization | $13,119,906 | $9,204,673 | $5,664,016 | $7,406,774 |
| Additional Paid In Capital | $84,090,966 | $64,370,465 | $51,867,336 | $47,855,521 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Dueto Related Parties Non Current | $1,723,733 | $2,323,733 | $2,923,733 | $3,523,733 |
| Pensionand Other Post Retirement Benefit Plans Current | $391,926 | $0 | - | - |
| Current Accrued Expenses | $3,237,846 | $2,597,502 | $2,360,968 | $2,162,363 |
| Dueto Related Parties Current | $600,000 | $600,000 | $600,000 | $600,000 |
| Other Short Term Investments | $14,927,165 | $10,433,535 | $8,293,663 | $9,992,900 |
| Treasury Shares Number | - | - | $0 | $44 |
| Treasury Stock | - | - | $0 | $2,932,000 |
Fetched: 2026-10-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-13,540,994 | $-7,857,309 | $-7,864,429 | $-8,730,732 |
| Operating Activities | ||||
| Operating Cash Flow | $-13,540,994 | $-7,857,309 | $-7,864,429 | $-8,480,732 |
| Cash Flow From Continuing Operating Activities | $-13,540,994 | $-7,857,309 | $-7,864,429 | $-8,480,732 |
| Operating Gains Losses | - | - | - | $-493,237 |
| Investing Activities | ||||
| Investing Cash Flow | $-4,277,775 | $-1,888,282 | $2,188,316 | $-10,149,121 |
| Cash Flow From Continuing Investing Activities | $-4,277,775 | $-1,888,282 | $2,188,316 | $-10,149,121 |
| Capital Expenditure | - | - | - | $-250,000 |
| Financing Activities | ||||
| Financing Cash Flow | $18,014,135 | $10,967,736 | $5,216,683 | $14,007,708 |
| Cash Flow From Continuing Financing Activities | $18,014,135 | $10,967,736 | $5,216,683 | $14,007,708 |
| Net Other Financing Charges | $18,014,135 | $10,967,736 | $5,216,683 | $14,319,378 |
| Other | ||||
| End Cash Position | $3,818,096 | $3,623,343 | $2,401,198 | $2,860,628 |
| Beginning Cash Position | $3,623,343 | $2,401,198 | $2,860,628 | $7,482,773 |
| Effect Of Exchange Rate Changes | $-613 | $0 | - | - |
| Changes In Cash | $195,366 | $1,222,145 | $-459,430 | $-4,622,145 |
| Net Investment Purchase And Sale | $-4,277,775 | $-1,888,282 | $2,188,316 | $-9,899,121 |
| Sale Of Investment | $7,986,294 | $15,366,000 | $20,279,000 | $0 |
| Purchase Of Investment | $-12,264,069 | $-17,254,282 | $-18,090,684 | $-9,899,121 |
| Change In Working Capital | $1,232,280 | $-2,137 | $95,447 | $-94,351 |
| Change In Payables And Accrued Expense | $1,325,128 | $275,955 | $53,924 | $-217,806 |
| Change In Payable | $1,325,128 | $275,955 | $53,924 | $-217,806 |
| Change In Account Payable | $1,325,128 | $275,955 | $53,924 | $-217,806 |
| Change In Prepaid Assets | $-92,848 | $-278,092 | $41,523 | $123,455 |
| Stock Based Compensation | $1,147,236 | $1,258,890 | $1,094,549 | $764,007 |
| Unrealized Gain Loss On Investment Securities | $-215,855 | $-251,590 | $-489,079 | $-93,779 |
| Depreciation Amortization Depletion | $100,000 | $100,000 | $103,706 | $104,043 |
| Depreciation And Amortization | $100,000 | $100,000 | $103,706 | $104,043 |
| Amortization Cash Flow | $100,000 | $100,000 | $103,706 | $104,043 |
| Amortization Of Intangibles | $100,000 | $100,000 | $103,706 | $104,043 |
| Net Income From Continuing Operations | $-15,804,655 | $-8,962,472 | $-8,686,573 | $-9,381,496 |
| Asset Impairment Charge | - | $0 | $17,521 | $0 |
| Repayment Of Debt | - | - | $0 | $-311,670 |
| Net Issuance Payments Of Debt | - | - | $0 | $-311,670 |
| Net Short Term Debt Issuance | - | - | $0 | $-311,670 |
| Short Term Debt Payments | - | - | $0 | $-311,670 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-250,000 |
| Purchase Of Intangibles | - | - | $0 | $-250,000 |
| Issuance Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
| Other Non Cash Items | - | - | - | $714,081 |
| Gain Loss On Investment Securities | - | - | - | $-77,237 |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Change In Accrued Expense | - | - | - | - |
| Change In Interest Payable | - | - | - | - |
Fetched: 2026-10-24